Surveyor Capital

Portfolio Co Investors 2026 for Surveyor Capital: investors, rounds, and co-investor patterns from StartupFundraising.com research, updated for 2026.

Surveyor Capital accounts for 48 tracked companies with verified cap-table data, 48 of which disclose round sizes totalling $10B. The median disclosed raise is $165M, and the largest is ElevateBio at $1.3B, ahead of ACELYRIN ($758M) and Point Biopharma ($650M).

The names that recur most often on these co-invested cap tables are Surveyor Capital (48 companies), Logos Capital (18 companies), Cormorant Asset Management (14 companies), Janus Henderson Investors (14 companies), RA Capital Management (12 companies), OrbiMed (10 companies). By latest disclosed round, the market skews Series B (16), Series A (11), Series C (10), Series D (3).

Best funded Surveyor Capital companies

  1. ElevateBio — $1.3B (latest: Series D)
  2. ACELYRIN — $758M (latest: Series C)
  3. Point Biopharma — $650M (latest: IPO)
  4. Neumora Therapeutics — $500M (latest: Series A)
  5. Talaris Therapeutics — $365M (latest: Other Equity)
  6. Metagenomi — $300M (latest: Series B)
  7. Nuvation Bio — $275M (latest: Series A)
  8. NiKang Therapeutics — $260M (latest: Series C)
  9. Boundless Bio — $256M (latest: Series C)
  10. Enliven Therapeutics — $230M (latest: Growth)
  11. Soley Therapeutics — $220M (latest: Series C)
  12. Verve Therapeutics — $216M (latest: Series B)
  13. Neuron23 — $214M (latest: Series D)
  14. VelosBio — $213M (latest: Seed)
  15. Remix Therapeutics — $211M (latest: Growth)

Surveyor Capital — related firms and companies (51)

Surveyor Capital alternatives · All research reports